Immuneering Corporation Appoints Andrew Gengos as Chief Financial Officer

On June 11, 2026, Immuneering Corporation appointed Andrew Gengos as its new Chief Financial Officer and Treasurer, effective on or before July 16, 2026. Mr. Gengos succeeds Mallory Morales as the principal financial officer, though Ms. Morales will remain with the company as Senior Vice President Finance and Chief Accounting Officer. Mr. Gengos brings extensive industry experience, having previously served as CFO at Terns Pharmaceuticals and LeonaBio, and as Chief Business Officer at Cyteir Therapeutics. His compensation package includes an annual base salary of $530,000, a target annual performance bonus of 40%, and an inducement grant of options to purchase 650,000 shares of common stock. The agreement also provides for various severance benefits in the event of termination without cause or resignation for good reason, including enhanced benefits if such termination occurs in connection with a change in control of the company.